Table 2 adjuvant cehmotherapy
From: Cardiovascular disease events within 5 years after a diagnosis of breast cancer
N = 682 | N (%) | |
|---|---|---|
Chemotherapy (N = 682) | Y | 256 (37.5%) |
N | 426 (62.5%) | |
Neo-adjuvant chemotherapy (N = 682) | Y | 22 (3.2%) |
N | 660 (96.8%) | |
Adjuvant chemotherapy (N = 682) | Y | 234 (34.3%) |
N | 448 (65.7%) | |
Chemotherapy with anthracyclines (N = 256) | Y | 174 (68%) |
N | 82 (32%) | |
3 FEC 100–3 DOCETAXEL (N = 256) | Y | 74 (28.9%) |
N | 182 (71.1%) | |
6 TAC (N = 256) | Y | 79 (30.9%) |
N | 177 (69.1%) | |
6 FEC (N = 256) | Y | 1 (0.4%) |
N | 117 (45.7%) | |
4 AC-4 DOCETAXEL (N = 256) | Y | 19 (7.4%) |
N | 237 (92.6%) | |
4 AC-12 PACLITAXEL WEEKLY: (N = 256) | Y | 1 (0.4%) |
N | 255 (99.6%) | |
Chemotherapy without anthracyclines (N = 256) | Y | 82 (32%) |
N | 174 (68%) | |
6 DOCETAXEL-CARBOPLATINE (N = 256) | Y | 4 (1.6%) |
N | 251 (98%) | |
4 DOCETAXEL-ENDOXAN (N = 256) | Y | 78 (30.5%) |
N | 178 (69.5%) |